221 related articles for article (PubMed ID: 29665393)
21. Toward a Novel Drug To Target the EGF-EGFR Interaction: Design of Metabolically Stable Bicyclic Peptides.
Guardiola S; Seco J; Varese M; Díaz-Lobo M; García J; Teixidó M; Nevola L; Giralt E
Chembiochem; 2018 Jan; 19(1):76-84. PubMed ID: 29105934
[TBL] [Abstract][Full Text] [Related]
22. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.
Fan YX; Wong L; Johnson GR
Biochem J; 2005 Dec; 392(Pt 3):417-23. PubMed ID: 16122376
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone alters epidermal growth factor receptor binding affinity via activation of extracellular signal-regulated kinases in 3T3-F442A cells.
Huang Y; Chang Y; Wang X; Jiang J; Frank SJ
Endocrinology; 2004 Jul; 145(7):3297-306. PubMed ID: 15070853
[TBL] [Abstract][Full Text] [Related]
24. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
25. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling.
Yu X; Sharma KD; Takahashi T; Iwamoto R; Mekada E
Mol Biol Cell; 2002 Jul; 13(7):2547-57. PubMed ID: 12134089
[TBL] [Abstract][Full Text] [Related]
26. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
27. Contribution of the transforming growth factor alpha B-loop beta-sheet to binding and activation of the epidermal growth factor receptor.
Richter A; Drummond DR; MacGarvie J; Puddicombe SM; Chamberlin SG; Davies DE
J Biol Chem; 1995 Jan; 270(4):1612-6. PubMed ID: 7829492
[TBL] [Abstract][Full Text] [Related]
28. Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor.
Summerfield AE; Hudnall AK; Lukas TJ; Guyer CA; Staros JV
J Biol Chem; 1996 Aug; 271(33):19656-9. PubMed ID: 8702666
[TBL] [Abstract][Full Text] [Related]
29. Development of an epidermal growth factor derivative with EGFR blocking activity.
Panosa C; Tebar F; Ferrer-Batallé M; Fonge H; Seno M; Reilly RM; Massaguer A; De Llorens R
PLoS One; 2013; 8(7):e69325. PubMed ID: 23935985
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail.
Bishayee A; Beguinot L; Bishayee S
Mol Biol Cell; 1999 Mar; 10(3):525-36. PubMed ID: 10069801
[TBL] [Abstract][Full Text] [Related]
31. Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding.
Taylor ES; Pol-Fachin L; Lins RD; Lower SK
Proteins; 2017 Apr; 85(4):561-570. PubMed ID: 28019699
[TBL] [Abstract][Full Text] [Related]
32. Binding of single-mutant epidermal growth factor (EGF) ligands alters the stability of the EGF receptor dimer and promotes growth signaling.
Pascarelli S; Merzhakupova D; Uechi GI; Laurino P
J Biol Chem; 2021 Jul; 297(1):100872. PubMed ID: 34126069
[TBL] [Abstract][Full Text] [Related]
33. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
[TBL] [Abstract][Full Text] [Related]
34. A structure-based model for ligand binding and dimerization of EGF receptors.
Klein P; Mattoon D; Lemmon MA; Schlessinger J
Proc Natl Acad Sci U S A; 2004 Jan; 101(4):929-34. PubMed ID: 14732694
[TBL] [Abstract][Full Text] [Related]
35. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity.
Lax I; Fischer R; Ng C; Segre J; Ullrich A; Givol D; Schlessinger J
Cell Regul; 1991 May; 2(5):337-45. PubMed ID: 1716463
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
37. Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.
Ramirez UD; Nikonova AS; Liu H; Pecherskaya A; Lawrence SH; Serebriiskii IG; Zhou Y; Robinson MK; Einarson MB; Golemis EA; Jaffe EK
BMC Cancer; 2015 May; 15():436. PubMed ID: 26016476
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
39. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
Holbrook MR; Slakey LL; Gross DJ
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
[TBL] [Abstract][Full Text] [Related]
40. Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor.
Woltjer RL; Lukas TJ; Staros JV
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7801-5. PubMed ID: 1380167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
